Insulin Resistance as Primary Pathogenesis in Newly Diagnosed, Drug naïve Type 2 Diabetes Patients in Korea
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Other: HOMA-IR
- Registration Number
- NCT01154244
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The purpose of this study is investigating the clinical characteristics of newly diagnosed, drug naïve type 2 diabetic patients according to insulin secretion and insulin resistance.
- Detailed Description
Primary Objective:To investigate whether insulin resistance or insulin deficiency is primary in the pathogenesis of type 2 diabetes mellitus in Korea Secondary Objectives:To investigate proportion of patients with severe insulin deficiency at diagnosis,To investigate proportion of metabolic syndrome in patients with newly diagnosed, drug-naïve type 2 diabetes mellitus,To investigate proportion of obesity in patients with newly diagnosed, drug-naïve type 2 diabetes mellitus
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1439
Newly diagnosed, drug naïve type 2 DM patients who gave informed consent, Diagnosis of type 2 DM will be made according to ADA guideline 2009
Patients age under 18 years
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Drug naive type II DM HOMA-IR Newly diagnosed type II Diabetes Mellitus
- Primary Outcome Measures
Name Time Method insulin resistance assessed using HOMA-IR within 3months after DM diagnosis
- Secondary Outcome Measures
Name Time Method proportion of patients with severe insulin deficiency assessed using C-peptide within 3months after DM diagnosis proportion of metabolic syndrome in patients within 3months after DM diagnosis proportion of obesity in patients within 3months after DM diagnosis
Trial Locations
- Locations (1)
GSK Investigational Site
🇰🇷Seoul, Korea, Republic of